Aims: Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare Epstein-Barr virus (EBV) associated cancer, histologically indistinguishable from nasopharyngeal carcinoma (NPC). Somatostatin receptor type 2 (SSTR2), is a bonafide theranostic target in neuroendocrine tumour. It is also expressed in NPC, based on autoradiography and positron emission tomography (PET). SSTR2 expression has not been reported in PLELC. We aim to investigate SSTR2 expression and co-localization with EBV positive PLELC cells using immunohistochemistry (IHC) and investigate its clinical significance Methodology: Clinical demographics include age, gender, TNM staging, EBV titre, smoking status, survival and treatment regime. Archival formalin fixed, paraffin embedded (FFPE) tissue of PLELC (2003 -2016) at National Cancer Centre Singapore were retrieved. IHC staining for SSTR2 and Epstein-Barr encoding region in-situ hybridisation (EBER-ISH) were performed using a dual-staining technique.
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Result:
We report clinical data from 20 PLELC patients. The median age at diagnosis was 56.5; 80% of the patients were female and all non-smokers. 55% of the patients have stage IV disease. Median OS was 57.7 months (95% CI, 21.8 to undefined).
Sixteen out of 20 patients stained positive for SSTR2 on IHC. SSTR2 expression colocalised with EBER positive cells. Nine out of 11 (82%) patients with stage IV PLELC stained positive for SSTR2 while 7 out of 9 (78%) stage I-III disease stained positive. 
Conclusion:
In PLELC, high levels of SSTR2 IHC expression is reported with co-localisation with EBV-infected cells. A high proportion of stage IV patients had SSTR2 positive tumours. This study opens up the possibility of using SSTR2 theranostics for these patients.
